PITTSTON, ME -- (Marketwire) -- 02/21/13 -- YaFarm Technologies, Inc. (PINKSHEETS: YFRM) (YaFarm, or the Company) announced today that The Integrative Stem Cell Institute (ISCI), a premier provider of point-of-care, stem cell-based therapies, has announced the appointment of Dr Eduardo Cervera Ceballos, MD as its Medical and Laboratory Director.
Dr Cervera, a licensed hematologist, is currently a Director at the National Cancer Institute in Mexico City. He is a graduate of the Autonomous University of the Yucatan and did his post-doctoral fellowship at the Regional Hospital Locarno and Hospital San Giovanni in Switzerland. Dr Cervera is a member of several prestigious associations, including the Internal Medicine Association of México, the European Society for Medical Oncology, the American Society of Clinical Oncology and the Oncology Society of Central American and the Caribbean. Dr Cervera is widely published with over 4 dozen articles, has developed curriculum for organizations such as American Society of Hematology, the American College of Physicians and spoken at several international conferences.
"Dr Cervera is a highly respected physician and researcher," says David Audley, CEO of the ISCI. "He brings years of clinical experience and laboratory expertise to the ISCI." Dr Cervera will also serve on the executive leadership of the ISCI and provide oversight to the laboratory and medical staff of the Institute. "Dr Cervera," continues Mr Audley, "will provide direct leadership to the medical and lab services that define our clinical studies. I have no doubt that under his oversight the ISCI becomes the standard for the field of regenerative medicine."
About Integrative Stem Cell Institute (ISCI)
The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at www.iscelli.com
SAFE HARBOR STATEMENT
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.